Clinical and surgical outcomes of splenectomy for autoimmune hemolytic anemia.
Autoimmune hemolytic anemia
Complete response
Partial response
Splenectomy
Journal
Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
06
06
2021
accepted:
07
02
2022
pubmed:
24
2
2022
medline:
19
7
2022
entrez:
23
2
2022
Statut:
ppublish
Résumé
We investigated short and long-term remission rates after splenectomy in patients with primary and secondary autoimmune hemolytic anemia (AIHA). All adults who underwent splenectomy for primary or secondary AIHA at a single center (2004-2018) were retrospectively reviewed. Short-term response was determined at 30-day postoperatively and long-term at one year. Complete response was defined as hemoglobin > 10 g/dL without hemolysis, transfusions, or need for additional medical therapy for > 6 months. Short-term complete response was attained in 22 of 36 patients (61%), partial response in 3 (8%), no response in 11 (31%). The response rate at 1 year was complete in 14/36 (39%), partial in 14 (39%), and 8 non-response (22%). At last available follow-up (median 33.1 months (IQR 19-59), 16/37 patients had experienced a complete response (43%), 14 partial response (38%), 7 non-response (19%). 80% of partial responders with primary AIHA required maintenance therapy compared to 100% with secondary AIHA. Splenectomy is associated with short- and long-term improvement in anemia and hemolysis in the majority of patients with AIHA. Immunosuppressants remain important supplemental therapy.
Identifiants
pubmed: 35194660
doi: 10.1007/s00464-022-09116-x
pii: 10.1007/s00464-022-09116-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5863-5872Informations de copyright
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
Références
Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, Lunghi M, Tassinari C, Alfinito F, Ferrari A, Leporace AP, Niscola P, Carpenedo M, Boschetti C (2014) Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. https://doi.org/10.1182/blood-2014-06-583021
doi: 10.1182/blood-2014-06-583021
pubmed: 25232059
Bradley C, Gehrs RCF (2018) Autoimmune hemolytic anemia. Am J Hematol. https://doi.org/10.1016/j.mcna.2016.09.007
doi: 10.1016/j.mcna.2016.09.007
Giannouli S, Voulgarelis M, Ziakas PD, Tzioufas AG (2006) Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis. https://doi.org/10.1136/ard.2005.041673
doi: 10.1136/ard.2005.041673
pubmed: 16322082
Böttiger LE, Westerholm B (1973) Acquired haemolytic anaemia: I. Incidence and aetiology. Acta Med Scand. https://doi.org/10.1111/j.0954-6820.1973.tb10567.x
doi: 10.1111/j.0954-6820.1973.tb10567.x
pubmed: 4589793
Liebman HA, Weitz IC (2017) Autoimmune hemolytic anemia. Med Clin NA. https://doi.org/10.1016/j.mcna.2016.09.007
doi: 10.1016/j.mcna.2016.09.007
Dierickx D, Kentos A, Delannoy A (2015) The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. Blood. https://doi.org/10.1182/blood-2015-01-588392
doi: 10.1182/blood-2015-01-588392
pubmed: 26384356
Barcellini W, Zaja F, Zaninoni A et al (2013) Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. https://doi.org/10.1111/ejh.12199
doi: 10.1111/ejh.12199
pubmed: 24033754
Sys J, Provan D, Schauwvlieghe A, Vanderschueren S, Dierickx D (2017) The role of splenectomy in autoimmune hematological disorders: outdated or still worth considering? Blood Rev. https://doi.org/10.1016/j.blre.2017.01.001
doi: 10.1016/j.blre.2017.01.001
pubmed: 28077241
Coon WW (1985) Splenectomy in the treatment of hemolytic anemia. Arch Surg. https://doi.org/10.1001/archsurg.1985.01390290099017
doi: 10.1001/archsurg.1985.01390290099017
pubmed: 3985801
Allgood JW, Chaplin H (1967) Idiopathic acquired autoimmune hemolytic anemia: a review of forty-seven cases treated from 1955 through 1965. Am J Med. https://doi.org/10.1016/0002-9343(67)90168-4
doi: 10.1016/0002-9343(67)90168-4
pubmed: 6034957
Akpek G, McAneny D, Weintraub L (1999) Comparative response to splenectomy in coombs-positive autoimmune hemolytic anemia with or without associated disease. Am J Hematol. https://doi.org/10.1002/(sici)1096-8652(199906)61:2%3c98::aid-ajh4%3e3.0.co;2-g
doi: 10.1002/(sici)1096-8652(199906)61:2<98::aid-ajh4>3.0.co;2-g
pubmed: 10367787
Zanella A, Barcellini W (2014) Treatment of autoimmune hemolytic anemias. Haematologica. https://doi.org/10.3324/haematol.2014.114561
doi: 10.3324/haematol.2014.114561
pubmed: 25271314
pmcid: 4181250
Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A et al (2009) Rituximab in autoimmune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med. https://doi.org/10.1111/j.1365-2796.2009.02126.x
doi: 10.1111/j.1365-2796.2009.02126.x
pubmed: 19549092
Crowther M, Chan YLT, Garbett IK, Lim W, Vickers MA, Crowther MA (2011) Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood. https://doi.org/10.1182/blood-2011-05-347708
doi: 10.1182/blood-2011-05-347708
pubmed: 21911832
pmcid: 5524527
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. https://doi.org/10.1097/01.sla.0000133083.54934.ae
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 15570203
pmcid: 1356513
Rashid SA (2014) Accessory spleen: prevalence and multidetector CT appearance. Malays J Med Sci 21(4):18–23
pubmed: 25977617
pmcid: 4418109
Bowdler AJ (1976) The role of the spleen and splenectomy in autoimmune hemolytic disease. Semi Hematol 13(4):335–348
Zupanska B, Sylwestrowicz T, Pawelski S (1981) The results of prolonged treatment of autoimmune haemolytic anaemia. Haematologia (Budap) 14(4):425–433
Rodeghiero F, Ruggeri M (2008) Is splenectomy still the gold standard for the treatment of chronic ITP? Am J Hematol. https://doi.org/10.1002/ajh.21109,February2008
doi: 10.1002/ajh.21109,February2008
pubmed: 18839438
Palandri F, Polverelli N, Sollazzo D et al (2016) Have splenectomy rate and main outcomesof ITP changed after the introduction of new treatments? A monocentric study inthe outpatient setting during 35 years. Am J Hematol. https://doi.org/10.1002/ajh.24310
doi: 10.1002/ajh.24310
pubmed: 27701770
Reynaud Q, Durieu I, Dutertre M et al (2015) Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun Rev. https://doi.org/10.1016/j.autrev.2014.11.014
doi: 10.1016/j.autrev.2014.11.014
pubmed: 25497766
Gómez-Almaguer D, Solano-Genesta M, Tarín-Arzaga L et al (2010) Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. https://doi.org/10.1182/blood-2010-06-291831
doi: 10.1182/blood-2010-06-291831
pubmed: 20841509
Rossi G, Gramegna D, Paoloni F et al (2018) Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood. https://doi.org/10.1182/blood-2018-03-835413
doi: 10.1182/blood-2018-03-835413
pubmed: 30455381
pmcid: 6238190
Jasinski S, Weinblatt ME, Glasser CL (2017) Sirolimus as an effective agent in the treatment of immune thrombocytopenia (ITP) and evans syndrome (ES): a single institution’s experience. J Pediatr Hematol Oncol. https://doi.org/10.1097/MPH.0000000000000818
doi: 10.1097/MPH.0000000000000818
pubmed: 28267088
Park JA, Lee HH, Kwon HS, Baik CR, Song SA, Lee JN (2016) Sirolimus for refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: a case report and literature review of the treatment of post-transplant autoimmune hemolytic anemia. Transfus Med Rev. https://doi.org/10.1016/j.tmrv.2015.09.001
doi: 10.1016/j.tmrv.2015.09.001
pubmed: 26481836
Neave L, Wilson A, Lissack M, Scully M (2018) Severe refractory idiopathic warm autoimmune haemolytic anaemia responsive to complement inhibition with eculizumab. BMJ Case Rep. https://doi.org/10.1136/bcr-2018-226429
doi: 10.1136/bcr-2018-226429
pubmed: 30567234
pmcid: 6301595
Ma K, Caplan S (2016) Refractory IgG warm autoimmune hemolytic anemia treated with eculizumab: a novel application of anticomplement therapy. Case Rep Hematol. https://doi.org/10.1155/2016/9181698
doi: 10.1155/2016/9181698
pubmed: 27092282
pmcid: 4820603
Schuetz C, Hoenig M, Moshous D, Weinstock C, Castelle M, Bendavid M, Shimano K, Tolbert V, Schulz AS, Dvorak CC (2018) Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv. https://doi.org/10.1182/bloodadvances.2018020883
doi: 10.1182/bloodadvances.2018020883
pubmed: 30291113
pmcid: 6177653
Hess J, Su L, Nizzi F, Beebe K, Magee K, Salzberg D, Stahlecker J, Miller HK, Adams RH, Ngwube A (2018) Successful treatment of severe refractory autoimmune hemolytic anemia after hematopoietic stem cell transplant with abatacept. Transfusion. https://doi.org/10.1111/trf.14907
doi: 10.1111/trf.14907
pubmed: 30592057
Allan-Schrimscher C, Beebe KL, Magee KH, McNulty A, Salzberg D, Stahlecker J, Miller HK, Adams RH, Ngwube A (2018) Successful treatment of severe autoimmune hemolytic anemia after hematopoietic stem cell transplant with abatacept: a case series. Tansplant Cell Ther. https://doi.org/10.1016/j.bbmt.2017.12.059
doi: 10.1016/j.bbmt.2017.12.059
Balague C, Targarona EM, Cerdan G, Novell J, Montero O, Bendahan G, Garcia A, Pey A, Vela S, Diaz M, Trias M (2004) Long-term outcome after laparoscopic splenectomy related to hematologic diagnosis. Surgl Endosc. https://doi.org/10.1007/s00464-003-9092-y
doi: 10.1007/s00464-003-9092-y
Bisharat N, Omari H, Lavi I, Raz R (2001) Risk of infection and death among post-splenectomy patients. J Infect. https://doi.org/10.1053/jinf.2001.0904
doi: 10.1053/jinf.2001.0904
pubmed: 11798256
Krauth MT, Lechner K, Neugebauer EAM, Pabinger I (2008) The postoperative splenic/portal vein thrombosis after splenectomy and its prevention: AN unresolved issue. Haematologica. https://doi.org/10.3324/haematol.12682,June12
doi: 10.3324/haematol.12682,June12
pubmed: 18556406
Kyaw MH, Holmes EM, Toolis F et al (2006) Evaluation of severe infection and survival after splenectomy. Am J Med. https://doi.org/10.1016/j.amjmed.2005.07.044,March
doi: 10.1016/j.amjmed.2005.07.044,March
pubmed: 16490477